系统穿刺活检检出前列腺癌的可能性与腺体体积及穿刺针数的关系
基于42例患者的前列腺穿刺数据模拟系统活检,评估腺体体积和穿刺针数对临床显著前列腺癌检出概率及MRI感兴趣区采样比例的影响。结果显示检出概率随模拟针数增加而升高,随腺体体积增大而显著降低;对于体积≥60 cm³的腺体,仅行12针系统活检采样不充分,可能导致前列腺癌漏诊。
要点
- 系统活检检出临床显著前列腺癌的概率随模拟针数增加而升高,随腺体体积增大而显著降低。
- MRI感兴趣区被系统活检采样的比例随模拟针数增加而升高,体积≥60 cm³腺体低于<60 cm³腺体。
- 在较小腺体中,常规12针系统活检可达到足够的癌症检出和感兴趣区采样,但在较大腺体中则不能。
核心结论
- 系统活检针数对临床显著前列腺癌检出效果的影响在很大程度上随腺体体积变化。
- 常规12针系统活检在较小腺体中可达到足够的癌症检出和感兴趣区采样,但在较大腺体中则不能。
- 在联合靶向活检或mpMRI阴性患者中,系统活检针数可根据前列腺体积调整。
- 对≥60 cm³腺体仅行12针系统活检会导致采样不充分和潜在的前列腺癌漏诊。
研究设计与样本
- 基于42例入组经直肠超声机器人辅助活检试验患者的数据,采用模拟方法模拟系统活检。
- 使用线性混合模型分析系统活检针数与前列腺体积对临床显著癌症检出概率及MRI感兴趣区采样百分比的关系。
主要发现
- 前列腺体积中位数47.16 cm³(IQR 35.61–65.57),感兴趣区体积中位数0.57 cm³(IQR 0.39–0.83),MRI PI-RADS v2.1评分中位数4.0(IQR 2–4)。
- 临床显著癌症检出概率随模拟系统活检针数增加而升高,并随前列腺体积增大而显著降低。
- MRI感兴趣区被系统活检采样的百分比随模拟针数增加而升高,且前列腺体积≥60 cm³者低于<60 cm³者。
临床怎么用
- 在联合靶向活检或mpMRI阴性患者中,系统活检针数可根据前列腺体积调整。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-biopsy multiparametric magnetic resonance imaging (mpMRI) of the prostate is used to conduct targeted prostate biopsy (TB), guided by ultrasound and registered (fused) to the MRI. Systematic biopsy (SB) continues to be used together with TB or in mpMRI-negative patients. There is insufficient evidence on how to use SB to inform clinical decision-making in the mpMRI era. The purpose of this study was to estimate the effect of prostate volume and number of SB cores on sampling clinically significant prostate cancer (csPCa) using a simulation method based on clinical data. METHODS: SBs were simulated using data from 42 patients enrolled in a transrectal ultrasound robot-assisted biopsy trial. Linear mixed models were used to examine the relationship between the number of SB cores and prostate volume on 1) clinically significant cancer detection probability (csCDP) and 2) percent of mpMRI depicted regions of interest (ROIs) sampled with the SB. RESULTS: Median values and interquartile range (IQR) were 47.16 cm3 (35.61-65.57) for prostate volume, 0.57 cm3 (0.39-0.83) for ROI volume, and 4.0 (2-4) for PI-RADS v2.1 scores on MRI. csCDP increased with the increasing number of simulated SB cores and decreased substantially with larger prostate volume. Similarly, the percent of ROIs sampled increased with the increasing number of simulated SB cores and was lower for prostate volumes ≥60 cm3 compared to glands <60 cm3. CONCLUSIONS: The effect of the number of SBs performed on detecting csPCa varies largely with gland volume. The common 12-core SB can achieve adequate cancer detection and sampling of ROIs in smaller glands, but not in larger glands. In addition to TB or in mpMRI-negative patients, the number of SB cores can be adjusted to prostate volume. Performing 12-core SB alone in ≥60 cm3 glands results in inadequate sampling and potential PCa underdiagnosis.
引用
- Rezaee ME, Macura KJ, Trock BJ, et al. Likelihood of sampling prostate cancer at systematic biopsy as a function of gland volume and number of cores. Prostate Cancer Prostatic Dis. 2024. PMID: 38184758. doi:10.1038/s41391-023-00780-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。